Hussman Strategic Advisors Inc. Acquires 2,100 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Hussman Strategic Advisors Inc. grew its stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 33.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,400 shares of the biotechnology company's stock after acquiring an additional 2,100 shares during the period. United Therapeutics comprises approximately 0.9% of Hussman Strategic Advisors Inc.'s holdings, making the stock its 20th biggest position. Hussman Strategic Advisors Inc.'s holdings in United Therapeutics were worth $2,964,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently modified their holdings of the company. Creative Planning raised its position in shares of United Therapeutics by 8.9% during the 3rd quarter. Creative Planning now owns 3,935 shares of the biotechnology company's stock valued at $1,410,000 after acquiring an additional 322 shares in the last quarter. Bleakley Financial Group LLC bought a new position in shares of United Therapeutics in the 3rd quarter worth about $240,000. Blue Trust Inc. boosted its holdings in shares of United Therapeutics by 45.1% in the 3rd quarter. Blue Trust Inc. now owns 1,405 shares of the biotechnology company's stock valued at $503,000 after buying an additional 437 shares during the period. Raymond James & Associates grew its position in shares of United Therapeutics by 1.7% during the 3rd quarter. Raymond James & Associates now owns 35,751 shares of the biotechnology company's stock valued at $12,811,000 after buying an additional 609 shares during the last quarter. Finally, Sequoia Financial Advisors LLC raised its stake in United Therapeutics by 12.6% during the third quarter. Sequoia Financial Advisors LLC now owns 723 shares of the biotechnology company's stock worth $259,000 after acquiring an additional 81 shares during the period. Institutional investors own 94.08% of the company's stock.

Insider Activity

In other news, Director Nilda Mesa sold 255 shares of the company's stock in a transaction on Monday, December 30th. The stock was sold at an average price of $355.77, for a total transaction of $90,721.35. Following the completion of the sale, the director now directly owns 5,528 shares of the company's stock, valued at $1,966,696.56. This represents a 4.41 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Paul A. Mahon sold 7,700 shares of the stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $374.37, for a total value of $2,882,649.00. Following the completion of the transaction, the executive vice president now owns 36,710 shares of the company's stock, valued at $13,743,122.70. This trade represents a 17.34 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 124,164 shares of company stock worth $45,398,793. Corporate insiders own 11.90% of the company's stock.

United Therapeutics Stock Down 1.7 %

NASDAQ UTHR traded down $6.26 on Friday, reaching $361.10. 407,154 shares of the stock traded hands, compared to its average volume of 347,037. United Therapeutics Co. has a 12 month low of $214.75 and a 12 month high of $417.82. The firm's fifty day simple moving average is $362.68 and its 200 day simple moving average is $360.19. The company has a market cap of $16.12 billion, a price-to-earnings ratio of 15.86, a P/E/G ratio of 0.99 and a beta of 0.57.

Wall Street Analyst Weigh In

UTHR has been the subject of several recent research reports. Argus upped their target price on United Therapeutics from $360.00 to $400.00 and gave the company a "buy" rating in a report on Thursday, October 31st. UBS Group raised their target price on United Therapeutics from $415.00 to $475.00 and gave the company a "buy" rating in a research note on Wednesday, January 8th. HC Wainwright boosted their price target on shares of United Therapeutics from $400.00 to $425.00 and gave the company a "buy" rating in a report on Thursday, October 31st. StockNews.com raised shares of United Therapeutics from a "buy" rating to a "strong-buy" rating in a report on Thursday, January 16th. Finally, Oppenheimer boosted their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the company an "outperform" rating in a research note on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, United Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $382.08.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.